Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia.

ABSTRACT:

Background and objective

Since 2016, new therapies have transformed the standard of care for lung cancer, creating a need for up-to-date evidence for health economic modelling. We developed a discrete event simulation of advanced lung cancer treatment to provide estimates of survival outcomes and healthcare costs in the Australian setting that can be updated as new therapies are introduced.

Methods

Treatment for advanced lung cancer was modelled under a clinician-specified treatment algorithm for Australia in 2022. Prevalence of lung cancer subpopulations was extracted from cBioPortal and the Sax Institute's 45 and Up Study, a large prospective cohort linked to cancer registrations. All costs were from the health system perspective for the year 2020. Pharmaceutical and molec

SUBMITTER: Ngo P 

PROVIDER: S-EPMC10570197 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature